Immunotherapy in inoperable stage III non-small cell lung cancer: a review

Natasha A Jain MD, Gregory A Otterson MD

Abstract

The leading cause of cancer-related deaths in the United States continues to be lung cancer. Approximately 25–30% of patients are diagnosed with locally advanced nonsmall cell lung cancer (NSCLC). Concurrent chemoradiation with a platinum-based doublet is the current standard of care for patients with inoperable stage III NSCLC. Unfortunately, only 15–20% of patients treated with definitive chemoradiation are alive at 5 years. Thus, there has been a major unmet need in this area. In this article, we summarize the current status and ongoing clinical trials incorporating immunotherapy into the management of inoperable stage III NSCLC, and we also present our perspective on the future directions.

Article Details

Article Type

Review

DOI

10.7573/dic.212578

Publication Dates

Accepted: ; Published: .

Citation

Jain NA, Otterson GA. Immunotherapy in inoperable stage III non-small cell lung cancer: a review. Drugs in Context 2019; 8: 212578. DOI: 10.7573/dic.212578

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.